OM:BIOG BBiotechs
BioGaia (OM:BIOG B) Could Be 28% Undervalued As Colus Launch Tests Growth Story
What the BioGaia Colus launch means for BioGaia stock
BioGaia (OM:BIOG B) has launched BioGaia Colus, a clinically tested probiotic capsule targeting the lower gastrointestinal tract, starting in the UK with a planned expansion into other selected markets.
Recent trading shows mixed momentum for BioGaia. The 1-day share price return of 1.76% and 7-day gain of 2.23% contrast with a 30-day share price decline of 5.09%, while the 5-year total shareholder return of 47.77% points to stronger...